Novelion Therapeutics (NVLNF) Stock Price, News & Analysis

Company Overview

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $0.70 to $0.75
• 50-Day Range: $0.70 to $0.70
• 52-Week Range: $0.51 to $1.00
• Volume: 26,900 shs
• Average Volume: 261,364 shs
• Market Capitalization: $13.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVLNF Stock Analysis - Frequently Asked Questions

How have NVLNF shares performed this year?

Novelion Therapeutics' stock was trading at $0.7020 at the beginning of the year. Since then, NVLNF stock has increased by 0.0% and is now trading at $0.7020.
View the best growth stocks for 2024 here.

How do I buy shares of Novelion Therapeutics?

Shares of NVLNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NVLNF
• CUSIP: N/A
• CIK: N/A
• Web: www.novelion.com
• Phone: 617-500-7867
• Fax: N/A
• Employees: 109
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $130.43 million
• Price / Sales: 0.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.69) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 19,619,000
• Free Float: N/A
• Market Cap: $13.77 million
• Optionable: Not Optionable
• Beta: 2.15